Strides Pharma Global partners with Kenox Pharmaceuticals
Political and trade tensions continue to escalate globally as Brazil vows retaliatory measures against steep U.S. tariffs imposed amid disputes over trade practices and political issues, signaling growing friction in bilateral relations. Meanwhile, Sweden has called on the European Union to suspend its trade agreement with Israel, condemning ongoing humanitarian concerns and violations related to the conflict in Gaza, urging the bloc to take decisive action. In a related development, the United States plans to move into a "phase two" of sanctions on Russia, intensifying economic pressure in response to Moscow's continued aggression in Ukraine. These interconnected events highlight rising geopolitical complexities impacting international trade, diplomatic relations, and global economic stability.
Strides Pharma Global has entered into a strategic product development partnership with Kenox Pharmaceuticals to bolster its nasal spray products pipeline for the U.S. market. This collaboration combines Strides’ manufacturing scale and commercial expertise with Kenox’s specialized formulation and development capabilities in orally inhaled and nasal drug products (OINDPs). The partnership aims to accelerate the development, regulatory filing, and launch of multiple nasal spray products across diverse therapeutic areas, focusing on producing affordable and high-quality medicines for patients in the United States.
Aditya Kumar, Executive Director of Business Development at Strides Pharma, emphasized the importance of nasal sprays as a key focus area for the company
and noted that the collaboration builds on the solid progress already made in this domain. With ongoing investments in Strides’ U.S. facility, these
products complement their strategy to expand in the nasal spray technology field. Dr. Sitaram Velaga, Founder and CEO of Kenox Pharmaceuticals, called
the partnership a significant milestone that validates Kenox’s expertise and enhances their ability to bring important treatments to patients globally
at reasonable costs.
The agreement reflects Strides' strategic expansion in the regulated U.S. pharmaceutical market and underscores its commitment to innovation and growth
within specialized drug delivery technologies. Specific product details remain confidential at this time. This partnership positions both companies
to address evolving patient needs via advanced nasal delivery solutions while boosting their competitive edge in a fast-growing segment of the pharmaceutical industry.
Strides Pharma Global has entered into a strategic product development partnership with Kenox Pharmaceuticals to bolster its nasal spray products pipeline for the U.S. market. This collaboration combines Strides’ manufacturing scale and commercial expertise with Kenox’s specialized formulation and development capabilities in orally inhaled and nasal drug products (OINDPs). The partnership aims to accelerate the development, regulatory filing, and launch of multiple nasal spray products across diverse therapeutic areas, focusing on producing affordable and high-quality medicines for patients in the United States.
Aditya Kumar, Executive Director of Business Development at Strides Pharma, emphasized the importance of nasal sprays as a key focus area for the company
and noted that the collaboration builds on the solid progress already made in this domain. With ongoing investments in Strides’ U.S. facility, these
products complement their strategy to expand in the nasal spray technology field. Dr. Sitaram Velaga, Founder and CEO of Kenox Pharmaceuticals, called
the partnership a significant milestone that validates Kenox’s expertise and enhances their ability to bring important treatments to patients globally
at reasonable costs.
The agreement reflects Strides' strategic expansion in the regulated U.S. pharmaceutical market and underscores its commitment to innovation and growth
within specialized drug delivery technologies. Specific product details remain confidential at this time. This partnership positions both companies
to address evolving patient needs via advanced nasal delivery solutions while boosting their competitive edge in a fast-growing segment of the pharmaceutical industry.